trending Market Intelligence /marketintelligence/en/news-insights/trending/notFvBWwzyVJdZN-Dkq9dg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Jazz Pharmaceuticals' sleep disorder drug gets EU approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Jazz Pharmaceuticals' sleep disorder drug gets EU approval

Dublin-based Jazz Pharmaceuticals PLC said that the European Commission approved Sunosi to treat a type of sleep disorder.

Sunosi, or solriamfetol, has been granted approval for the treatment of excessive daytime sleepiness, or EDS, associated with narcolepsy or obstructive sleep apnea, or OSA, for patients whose EDS has not been satisfactorily treated by primary OSA therapy.

Narcolepsy is a neurological disorder that affects the control of sleep and wakefulness. Patients experience excessive sleepiness and inability to regulate sleep-wake cycles normally. OSA is a disorder that causes breathing to repeatedly stop and start during sleep with excessive sleepiness as one of its major symptoms.

The EC's approval is based on data from a four-study program called Tones, which showed the medication to be superior to placebo in treating the disease.

The U.S. Food and Drug Administration approved Sunosi for the same indication in March 2019.